Abivax S.A.
NASDAQ:ABVXBiotechnology
-$0.62 today
- Market cap
- $7.34B
- Beta
- -0.20
- P/E (TTM)
- -18.1
- EPS (TTM)
- -$4.83
Volume 1.19M
Average 1.59M
ABVX Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Abivax S.A.NASDAQ: ABVX
Financing Cash Flow · Q2 FY2026 · quarter ended Jun 2026
Financing cash flow grows 348.8% year over year
Q2 FY2026 financing cash flow of €39.35M (cash outflow) rose 348.8% year over year. Over 3 fiscal years it compounded at +154.7% a year.
Context
- Financing cash flow increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
EUR · from the cash flow
- Latest · FY2025
- 531.94M EUR
- Year-over-year change
- +1785.8%
- 4-year CAGR
- +59.3%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 531.94M | +1785.8% |
| FY2024 | 2024-12-31 | 28.21M | -91.7% |
| FY2023 | 2023-12-31 | 340.57M | +957.3% |
| FY2022 | 2022-12-31 | 32.21M | -61.0% |
| FY2021 | 2021-12-31 | 82.68M | — |
Financing Cash Flow vs competitors
How ABVX compares with its peers on the latest reported figures
- Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +1785.8% is the highest of 10, against a peer median of +10.0%.
- Over three fiscal years its annual growth of +154.7% compares with a peer median of +84.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $759.69M USD | +242.5% | +93.5% | 839.5% | |
| FY2025 | €531.94M EUR | +1785.8% | +154.7% | — | |
| LTM Jun 2026 | $313M USD | +30.4% | +145.5% | 267.5% | |
| LTM Aug 2026 | $261.21M USD | +28.6% | +26.8% | 37.2% | |
| FY2025 | €232M EUR | +59.4% | +84.0% | 5175.1% | |
| LTM Mar 2026 | $141.69M USD | +10.0% | -4.0% | — | |
| LTM Mar 2026 | $107.35M USD | — | +221.5% | — | |
| LTM Mar 2026 | $102.81M USD | -191.7% | — | 44.2% | |
| LTM Mar 2026 | $52.19M USD | -29.8% | — | 623.8% | |
| LTM Mar 2026 | $20.66M USD | -94.1% | -57.0% | 9.5% | |
| LTM Mar 2026 | $15.99M USD | -76.2% | — | 27094.9% | |
| Peer median (excluding ABVX) | — | +10.0% | +84.0% | 445.7% | |
Competitors are the stored peer set for ABVX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (42.45M) | (60.74M) | (147.74M) | (176.24M) | (322.84M) |
| Depreciation & Amortization | 302K | 485K | 707K | 1.1M | 1.07M |
| Deferred Income Tax | 0 | 0 | 7.93M | 0 | 0 |
| Stock-Based Compensation | 828K | (1.16M) | 8.18M | 20.22M | 0 |
| Change in Working Capital | (668K) | (2M) | 21.27M | 1.42M | 3.51M |
| Accounts Receivables | (1.98M) | 312K | (14.23M) | 4.59M | 6.76M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.14M | (2.39M) | 31.76M | (3.44M) | 0 |
| Other Working Capital | 168K | 74K | 3.74M | 276K | (3.26M) |
| Other Non-Cash Items | (3.06M) | 9.49M | 9.65M | (577K) | 162.57M |
| Operating Cash Flow | (45.05M) | (53.94M) | (100.01M) | (154.07M) | (155.69M) |
| Capital Expenditures | (47K) | (323K) | (265K) | (643K) | (136.4K) |
| Acquisitions (Net) | (2.18M) | (2.91M) | 0 | 0 | 0 |
| Purchases of Investments | (9K) | (470K) | (9.35M) | 0 | (13.59M) |
| Sales of Investments | 0 | 218K | 741K | 0 | 480.27K |
| Other Investing Activities | (4M) | (8.57M) | (1.62M) | 16.4M | 68.2K |
| Investing Cash Flow | (6.23M) | (12.03M) | (10.5M) | 15.76M | (13.18M) |
| Debt Repayment | 19.13M | (9.71M) | 15.24M | 37.49M | (56.31M) |
| Common Stock Issued | 69.68M | 46.37M | 353.39M | 434K | 588.84M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (6.13M) | (4.45M) | (28.06M) | (9.71M) | (586.89K) |
| Financing Cash Flow | 82.68M | 32.21M | 340.57M | 28.21M | 531.94M |
| Effect of Forex Changes | 0 | 0 | (5.07M) | 2.38M | 26.29M |
| Net Change in Cash | 31.4M | (33.75M) | 224.99M | (107.72M) | 389.36M |
| Free Cash Flow | (45.1M) | (54.26M) | (100.28M) | (154.72M) | (155.83M) |
Abivax S.A.
NASDAQ:ABVX
Intrinsic Alpha fair value
Locked
Current Price
$83.83
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.